Documentation scienceplus.abes.fr version Bêta

À propos de : ▼Etanercept and ▼infliximab for rheumatoid arthritis        

AttributsValeurs
type
Is Part Of
Subject
Title
  • ▼Etanercept and ▼infliximab for rheumatoid arthritis
has manifestation of work
Abstract
  • &#9660Etanercept* (Enbrel - Wyeth) and&#9660infliximab* (Remicade - Schering Plough) belong to a new class of drugs that block the effects of tumour necrosis factor-alpha (TNF-α), a mediator of inflammation. Both are licensed for the treatment of patients with active rheumatoid arthritis who have responded inadequately to disease-modifying antirheumatic drugs (DMARDs). Here, we consider whether etanercept and infliximab offer advantages.
article type
publisher identifier
  • dtdt0107
Alternative Title
  • ▼Etanercept and ▼infliximab for rheumatoid arthritis
is part of this journal
PubMed ID
  • 11471515



Alternative Linked Data Documents: ODE     Content Formats:       RDF       ODATA       Microdata